Endometriosis Medical Services in China

Endometriosis is a chronic, estrogen-dependent gynecological disorder characterized by the presence of endometrial-like tissue—glands and stroma—outside the uterine cavity. This ectopic tissue most commonly implants on the ovaries, fallopian tubes, pelvic peritoneum, uterosacral ligaments, and rectovaginal septum; less frequently, it may involve distant sites such as the lungs, diaphragm, or abdominal scars. The disease is associated with inflammation, fibrosis, adhesion formation, and cyclic bleeding—leading to progressive pelvic pain, infertility, and organ dysfunction. Pathogenesis remains incompletely understood but involves multiple interrelated mechanisms: retrograde menstruation (with impaired immune clearance), coelomic metaplasia, lymphatic/vascular dissemination, stem cell recruitment, and genetic-epigenetic dysregulation. Recent evidence highlights aberrant neuroangiogenesis, macrophage polarization defects, and progesterone resistance as key contributors to lesion survival and symptom persistence. Epidemiologically, endometriosis affects approximately 6–10% of reproductive-age women globally—translating to over 190 million individuals. Among women with chronic pelvic pain, prevalence rises to 30–50%; among those with infertility, it reaches 25–50%. Risk factors include early menarche, short menstrual cycles (<27 days), heavy or prolonged menses, nulliparity, low body mass index (BMI), family history (first-degree relatives increase risk 7-fold), and certain genetic variants (e.g., SNPs in WNT4, GREB1, FN1). Protective factors include multiparity, late menarche, and long-term combined oral contraceptive use. Endometriosis profoundly impairs quality of life: 70–90% of affected women report moderate-to-severe dysmenorrhea, 50–70% experience deep dyspareunia, and 30–40% suffer chronic non-cyclical pelvic pain. Fatigue, gastrointestinal symptoms (bloating, diarrhea, constipation—often misdiagnosed as IBS), urinary urgency, and depression/anxiety are highly prevalent. Up to 40% report work absenteeism or reduced productivity; many delay diagnosis by 6–10 years due to normalization of pain and fragmented care pathways. The condition also correlates with increased risks of autoimmune disorders (e.g., SLE, Hashimoto’s thyroiditis), ovarian cancer (particularly clear-cell and endometrioid subtypes), and cardiovascular morbidity later in life. Early recognition, multidisciplinary management—including reproductive endocrinology, pain medicine, colorectal surgery, and urology—is essential to mitigate long-term sequelae and preserve fertility.

Endometriosis is a chronic, estrogen-dependent inflammatory disorder characterized by the presence of endometrial-like tissue outside the uterine cavity—commonly involving the ovaries, pelvic peritoneum, uterosacral ligaments, and rectovaginal septum. It affects approximately 10% of reproductive-age women globally and is strongly associated with pelvic pain, dysmenorrhea, dyspareunia, infertility, and reduced quality of life. Management in the Department of Reproductive Medicine is individualized, multidisciplinary, and guided by symptom severity, disease extent (per ASRM staging), fertility goals, patient age, and prior treatment response.

Conservative treatment forms the cornerstone of initial management, particularly for mild-to-moderate symptoms or when fertility preservation is paramount. This includes lifestyle modifications, physical therapy, and non-pharmacologic interventions. Pelvic floor physical therapy—delivered by certified specialists—addresses myofascial trigger points, hypertonicity, and neuromuscular dysfunction contributing to chronic pelvic pain. Dietary strategies emphasizing anti-inflammatory foods (e.g., omega-3 fatty acids, fiber-rich vegetables, low-glycemic-index carbohydrates) and avoidance of processed foods, excess alcohol, and trans fats may modestly reduce systemic inflammation and oxidative stress. Regular aerobic exercise (≥150 minutes/week) improves endorphin release, reduces estrogen bioavailability via adipose tissue modulation, and enhances autonomic regulation. Cognitive behavioral therapy (CBT) and mindfulness-based stress reduction are evidence-supported adjuncts for pain coping, emotional resilience, and functional restoration—particularly valuable given the high comorbidity with anxiety, depression, and central sensitization.

Pharmacologic therapy targets hormonal suppression, inflammation, and pain pathways. First-line agents include combined oral contraceptives (COCs), administered continuously (i.e., skipping placebo weeks) to suppress ovulation and decidualize ectopic implants. Progestin-only options—such as norethindrone acetate, dienogest, or the levonorgestrel-releasing intrauterine system (LNG-IUS)—are preferred in patients contraindicated for estrogen (e.g., migraine with aura, thrombophilia history). Dienogest, approved specifically for endometriosis in multiple jurisdictions including China, demonstrates potent anti-proliferative and anti-angiogenic effects on lesions with favorable tolerability. Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide) induce hypoestrogenic amenorrhea but require add-back therapy (e.g., low-dose estradiol/norethindrone) after 6 months to mitigate bone mineral density loss and vasomotor symptoms. GnRH antagonists (e.g., elagolix, relugolix) offer rapid, dose-titratable suppression with improved safety profiles and are increasingly utilized in refractory cases. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide symptomatic relief but lack disease-modifying effects; they are best used short-term and at lowest effective dose due to gastrointestinal and renal risks. Emerging agents—including aromatase inhibitors (e.g., letrozole) in combination with ovarian suppression—and selective progesterone receptor modulators (SPRMs) are under active investigation in clinical trials, especially for deep infiltrating endometriosis (DIE) and recurrent disease.

Surgical intervention is indicated for severe pain unresponsive to medical therapy, large endometriomas (>4 cm), suspected bowel or ureteral involvement, or infertility evaluation/treatment. Laparoscopy remains the gold standard: diagnostic confirmation requires histopathologic verification, while excisional surgery—performed by advanced laparoscopic surgeons trained in deep infiltrating endometriosis—is superior to ablation for long-term pain reduction and fertility outcomes. Complete excision of all visible lesions—including retrocervical, uterosacral, and rectovaginal nodules—minimizes recurrence risk. In cases of ovarian endometriomas, cystectomy with meticulous stripping technique preserves ovarian reserve better than coagulation or drainage alone. For DIE involving bowel or bladder, multidisciplinary collaboration with colorectal or urologic surgeons ensures safe resection and reconstruction. Hysterectomy with bilateral salpingo-oophorectomy is reserved for definitive management in patients who have completed childbearing and suffer debilitating symptoms refractory to all other modalities; however, even then, residual extrauterine disease may persist if not fully excised.

Treatment in China offers distinct advantages within the Reproductive Medicine framework. First, China’s national endometriosis referral network integrates tertiary reproductive centers with standardized surgical training programs—many led by surgeons certified by the Chinese Medical Association’s Endometriosis Task Force—ensuring high-volume expertise in complex excision. Second, domestic pharmaceutical innovation has accelerated access: dienogest and relugolix are widely available and reimbursed under the National Reimbursement Drug List (NRDL), reducing out-of-pocket burden. Third, integrative approaches are systematically incorporated: acupuncture—validated in RCTs for pain reduction and menstrual regulation—is routinely offered alongside conventional care in major centers such as Peking University Third Hospital and Shanghai Jiao Tong University Affiliated International Peace Maternity and Child Health Hospital. Fourth, China’s robust assisted reproductive technology (ART) infrastructure enables seamless transition from surgical management to IVF/ICSI when fertility is compromised, with cumulative live birth rates exceeding 60% per initiated cycle in endometriosis-related infertility managed at top-tier centers.

Post-treatment recovery emphasizes continuity and prevention. Patients undergoing surgery should avoid heavy lifting (>5 kg), sexual intercourse, and swimming for 4–6 weeks to allow peritoneal healing. Hormonal maintenance therapy—typically COCs or progestins—is strongly recommended postoperatively to delay recurrence; studies show a 50–70% reduction in 5-year recurrence with continuous suppression. Fertility counseling must be timely: for those desiring conception, spontaneous conception is encouraged within 6–12 months post-excision; beyond that, expedited ART referral is advised. Bone health monitoring (DEXA scan) is warranted for patients on prolonged GnRH analogues. Annual gynecologic evaluation—including transvaginal ultrasound with bowel preparation when indicated—facilitates early detection of recurrence. Psychological support remains integral: dedicated endometriosis nurse coordinators in leading Chinese hospitals provide longitudinal education, symptom tracking tools, and peer-support group linkages. Ultimately, optimal management hinges on shared decision-making, realistic expectation-setting, and lifelong partnership between patient and reproductive medicine specialist.